Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 42 for “"Azacitidine"”.

  1. FBXO11-Deficiency Promotes Azacitidine Resistance in Acute Myeloid Leukemia

    Hypomethylating agents (HMAs), including azacitidine (AZA) and decitabine (DAC), are widely used in clinical trials and constitute standard-of-care treatment for patients with high-risk acute myeloid leukemia (AML) who are ineligible for allogeneic stem cell transplantation. Although approximately …

    unsw Repository record for FBXO11-Deficiency Promotes Azacitidine Resistance in Acute Myeloid Leukemia (opens in a new tab)

  2. Identifying novel genetic targets that regulate azacitidine sensitivity in myelodysplastic syndromes

    Azacitidine (AZA) and Decitabine (DAC) are frontline hypomethylating agents (HMAs) effective at altering the natural course of Myelodysplastic Syndromes (MDS). Unfortunately, treatment resistance and failure are hallmarks of HMA therapy. Developing effective HMA combinatorial therapies is …

    unsw Repository record for Identifying novel genetic targets that regulate azacitidine sensitivity in myelodysplastic syndromes (opens in a new tab)

  3. Developing a tool to investigate the single-cell basis for response to azacitidine therapy in myelodysplastic syndromes

    … cells (HSPC). The primary therapeutic agent, azacitidine (AZA), is suboptimal, with a 50% response rate. AZA, a nucleoside analogue, is hypothesized to induce therapeutic effects by altering DNA methylation and RNA processing in HSPCs, leading to the reactivation of crucial genes for …

    unsw Repository record for Developing a tool to investigate the single-cell basis for response to azacitidine therapy in myelodysplastic syndromes (opens in a new tab)

  4. Targeting integrin alpha 5 and focal adhesion kinase to overcome azacitidine resistance in higher risk myelodysplastic syndromes

    … commonly progressing to acute myeloid leukaemia. Azacitidine (AZA) and decitabine are the only available therapies for higher risk myelodysplastic syndromes shown to improve the overall survival in these patients. However, primary and secondary resistance results in treatment failure in virtually …

    unsw Repository record for Targeting integrin alpha 5 and focal adhesion kinase to overcome azacitidine resistance in higher risk myelodysplastic syndromes (opens in a new tab)

  5. Targeting Venetoclax Plus Azacitidine Resistance And Leukemia Stem Cells In Acute Myeloid Leukemia Via The Novel Imipridone Onc213

    … care in the combination of venetoclax (VEN) and azacitidine (AZA) for AML patients who are ≥75 years or unfit for intensive chemotherapy. Though initially promising, resistance to the combination therapy is clinical challenge and VEN+AZA-resistant patients have dismal outcomes. Though these …

    wayne-thes Repository record for Targeting Venetoclax Plus Azacitidine Resistance And Leukemia Stem Cells In Acute Myeloid Leukemia Via The Novel Imipridone Onc213 (opens in a new tab)

  6. The Combined Treatment Efficacy of Anti-CD123 CAR T cells with Azacitidine for the Treatment of Acute Myeloid Leukaemia

    … with DNA methyltransferase inhibitors, such as azacitidine (AZA), was explored. AZA has previously been shown to upregulate the expression of leukaemia-associated antigens on AML thereby inducing more effective T cell responses. AZA was therefore combined with CD123 CAR T cells and evaluated in …

    adelaide Repository record for The Combined Treatment Efficacy of Anti-CD123 CAR T cells with Azacitidine for the Treatment of Acute Myeloid Leukaemia (opens in a new tab)

  7. Characterization of pro- and anti-apoptotic BCL-2 proteins regulating leukemogenesis in juvenile myelomonocytic leukemia (JMML)

    … recently, the DNA methyl transferase inhibitor azacitidine has been shown to have unprecedented activity against JMML, both in patients and the JMML xenograft mouse model. BH3-mimetics, small molecules inhibiting pro-survival BCL-2 proteins and thereby inducing apoptosis, were shown to be …

    freiburg-diss Repository record for Characterization of pro- and anti-apoptotic BCL-2 proteins regulating leukemogenesis in juvenile myelomonocytic leukemia (JMML) (opens in a new tab)

  8. Κυτταρική σηματοδότηση στο μυελοδυσπλαστικό σύνδρομο

    Azacitidine is the mainstay of high-risk myelodysplastic syndromes (MDS) therapy, but molecular predictors of response and the mechanisms of resistance to azacitidine remain largely unidentified. Deregulation of signaling via Stat3 and Stat5 in acute myeloid leukemia (AML) is associated with …

    greece Repository record for Κυτταρική σηματοδότηση στο μυελοδυσπλαστικό σύνδρομο (opens in a new tab)

  9. Investigating the impact of age-related chronic inflammation and epigenetic alterations on monocyte function

    … (IL-6)) and hypomethylation (i.e. 5- Azacitidine (AZA) treatment) impair monocyte functionality. Our data shows that 72 hours of IL-6 stimulation at 1 ng/mL suppresses pro-inflammatory cytokine production, whereas 5- Azacitidine treatment alone enhances it. Remarkably, combined IL-6 …

    laurentian Repository record for Investigating the impact of age-related chronic inflammation and epigenetic alterations on monocyte function (opens in a new tab)

  10. Epigenetic Modulation In Braf Mutated Metastatic Colorectal Cancer

    … BRAFV600E mCRC were treated with vemurafenib or azacitidine, alone or in combination, to assess for changes in tumor size. Tumors and cell lines exposed to azacitidine were analyzed for methylation status and for gene expression differences, with particular emphasis on genes identified from the …

    uthsc Repository record for Epigenetic Modulation In Braf Mutated Metastatic Colorectal Cancer (opens in a new tab)

  11. Oncogenic drivers and therapeutic vulnerabilities in pediatric rhabdomyosarcoma and melanoma

    … of the DNA methyltransferase inhibitor, azacitidine, and the MEK inhibitor (MEKi) trametinib. This combination therapy led to remarkable clinical and radiological responses, demonstrating a more durable effect than previously observed with trametinib monotherapy in advanced cases. In …

    freiburg-diss Repository record for Oncogenic drivers and therapeutic vulnerabilities in pediatric rhabdomyosarcoma and melanoma (opens in a new tab)

  12. Γονιδιακό /πρωτεϊνικό προφίλ και υποκείμενοι μηχανισμοί της αυτοφαγίας στις αιματολογικές κακοήθειες

    … levels, as well as to evaluate the effects of azacitidine, a hypomethylating agent widely used in the treatment of MDS, on these mechanisms. To achieve this objective, a combined experimental approach was employed, including the analysis of samples from patients with different prognostic …

    greece Repository record for Γονιδιακό /πρωτεϊνικό προφίλ και υποκείμενοι μηχανισμοί της αυτοφαγίας στις αιματολογικές κακοήθειες (opens in a new tab)

  13. An investigation of a novel cyclin-dependent kinase inhibitor as a treatment option for Acute Myeloid Leukaemia

    … cytarabine, or the hypomethylating agent azacitidine was assessed for synergistic activity. Combination studies using CompuSyn software were performed to investigate the most efficacious drug combination ratios which were utilised for further synergistic investigations. Using various …

    glasgow Repository record for An investigation of a novel cyclin-dependent kinase inhibitor as a treatment option for Acute Myeloid Leukaemia (opens in a new tab) Download PDF for An investigation of a novel cyclin-dependent kinase inhibitor as a treatment option for Acute Myeloid Leukaemia (opens in a new tab)

  14. (1) Rapic High Performance Liquid Chromatography of Cyclosporin A, Cimetidine, Cyclophosphamide, 5-Fluorouracil and 5-Azacytidine (2) Injection of Solutes in Stronger Solvents Than the Mobile Phase in Liquid Chromatography

    … analytical methods to quantitate the drugs 5-Azacitidine, Cimetidine, Cyclophosphamide, Cyclosporin A and 5-Fluorouracil from biological samples by using HPLC. 5-Azacitidine is isolated from plasma with acetonitrile and zinc sulfate. The solution is vortexed, centrifuged, filtered, and …

    marquette Repository record for (1) Rapic High Performance Liquid Chromatography of Cyclosporin A, Cimetidine, Cyclophosphamide, 5-Fluorouracil and 5-Azacytidine (2) Injection of Solutes in Stronger Solvents Than the Mobile Phase in Liquid Chromatography (opens in a new tab)

  15. Bypassing the Blood-Brain Barrier: A Physical and Pharmacological Approach for the Treatment of Metastatic Brain Tumors

    … to brain tumors, (b) evaluated the use of azacitidine as a single agent therapy for the treatment of brain metastasis of breast cancer and a potential molecular mechanism by which brain tropic cells are sensitized to hypomethylating agents, (c) determined the impact cannabidiol has on …

    wvu Repository record for Bypassing the Blood-Brain Barrier: A Physical and Pharmacological Approach for the Treatment of Metastatic Brain Tumors (opens in a new tab)

  16. Prevention of relapse of juvenile myelomonocytic leukemia (JMML) by inhibition of immune checkpoint CD47

    … synergistic effect observed when combined with azacitidine. These findings demonstrate that JMML macrophages remain functionally active and contribute to disease-associated inflammation, while CD47 blockade offers partial therapeutic benefit. Our study underscores the complex interplay between …

    freiburg-diss Repository record for Prevention of relapse of juvenile myelomonocytic leukemia (JMML) by inhibition of immune checkpoint CD47 (opens in a new tab)

  17. Proteomic analysis of Wnt and epigenetic regulatory protein networks in colorectal cancer

    … the changes to the nuclear-enriched proteome. 5-Azacitidine, a nucleoside analog able to trap and induce DNA-repair mediated degradation of Dnmt1, was utilized to degrade the protein over two time points. Nuclear-enriched proteomics analysis indicated that Dnmt1 degradation by this method …

    soton Download PDF for Proteomic analysis of Wnt and epigenetic regulatory protein networks in colorectal cancer (opens in a new tab)

  18. Ανοσολογική ρύθμιση των μυελικών νεοπλασιών

    … AML, MDS, and CMML undergoing treatment with azacitidine (AZA). Using MiXCR and VDJtools, we observed that patients with AML exhibit significantly higher TCR diversity compared to those with MDS or CMML, suggesting distinct mechanisms of immune evasion. Treatment with AZA increased TCR …

    greece Repository record for Ανοσολογική ρύθμιση των μυελικών νεοπλασιών (opens in a new tab)

Page 1 of 3